BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a growing $22.8 billion therapeutics market. Read the IPO report here ...

AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based ...

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

The Bank of Japan raised interest rates to their highest since the 2008 global financial crisis, underscoring its confidence that rising wages will keep inflation stable around its 2% target.